PARP1 and cancer: Further investigations revealed that compound (74) demonstrated, (i) concentration-dependent colony formation inhibition and migration in LoVo cells, (ii) synergistic anticancer efficacy (cell studies) with AZD-1390 (7), cisplatin, oxaliplatin, and PARP inhibitor, Olaparib against a panel of cancer cell lines, (iii) mild liver microsomal stability and appropriate pharmacokinetic profile (Figure 16).317